Popular New
- Improving lipid management in patients with acute coronary syndrome: The ACS Lipid EuroPath tool395 daysAtherosclerosis SupplementsRead
- Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives395 daysAtherosclerosis SupplementsRead
- Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project395 daysAtherosclerosis SupplementsRead
- Prevalence and relationship between metabolic syndrome and risk of cardiovascular disease: Evidence from two population-based studies395 daysAtherosclerosis SupplementsRead
- How registers could enhance knowledge and characterization of genetic dyslipidaemias: The experience of the LIPIGEN in Italy and of other networks for familial hypercholesterolemia395 daysAtherosclerosis SupplementsRead
- Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients395 daysAtherosclerosis SupplementsRead
- Hypercholesterolemia and cardiovascular disease: What to do before initiating pharmacological therapy395 daysAtherosclerosis SupplementsRead
- The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 study395 daysAtherosclerosis SupplementsRead
- ‘Diet and lifestyle’ in the management of dyslipidaemia and prevention of CVD - Understanding the level of knowledge and interest of European Atherosclerosis Society members395 daysAtherosclerosis SupplementsRead
- Lipid Clinics Network. Rationale and design of the EAS global project395 daysAtherosclerosis SupplementsRead
- Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk395 daysAtherosclerosis SupplementsRead
- Serum Bilirubin as Predictor of Infarct-Related Artery Patency, and In-Hospital Outcomes for ST- Elevation Myocardial Infarction and In-Hospital Outcomes Following Percutaneous Coronary Intervention590 daysAtherosclerosis SupplementsRead
- Diagnostic Accuracy of 256 Slices Computed Tomography Coronary Angiography in Post CABG Egyptian Patients590 daysAtherosclerosis SupplementsRead
- Correlation Between Epicardial Fat Thickness Assessed by Echocardiography and Coronary Artery Disease Severity in Patients Attending Suez Canal University Hospital590 daysAtherosclerosis SupplementsRead
- Trends in Early Invasive Management of Egyptian Patients with Acute Coronary Syndrome; Data from The Cross-Sectional Cardiorisk Project590 daysAtherosclerosis SupplementsRead
- Clinical Characteristics and Short Term Outcome of Multi-Vessel Coronary Artery Disease Patients Presented with AMI- Single Center Experience590 daysAtherosclerosis SupplementsRead
- Cardiovascular Predictors of Stroke in Patients with Sinus Rhythm Versus Patients with Atrial Fibrillation in Suez Canal University Hospital590 daysAtherosclerosis SupplementsRead
- ACS in CKD Patients590 daysAtherosclerosis SupplementsRead
- Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) consensus on the usage of pro protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors590 daysAtherosclerosis SupplementsRead
- Exercise-Based Cardiac Rehabilitation in Patients with Acute Coronary Syndrome590 daysAtherosclerosis SupplementsRead
- Lipoprotein apheresis – Shortening of treatment intervals reduces cardiovascular events: Case reports590 daysAtherosclerosis SupplementsRead
- Homozygous familial hypercholesterolaemia in childhood – The first case report in Southeast Europe590 daysAtherosclerosis SupplementsRead
- A successful term pregnancy with severe hypertriglyceridaemia and acute pancreatitis. Clinical management and review of the literature590 daysAtherosclerosis SupplementsRead
- A complicated pregnancy in homozygous familial hypercholesterolaemia treated with lipoprotein apheresis: A case report590 daysAtherosclerosis SupplementsRead
- Kidney and liver are the main organs of expression of a key metabolic enzyme alanine:glyoxylate aminotransferase 2 in humans590 daysAtherosclerosis SupplementsRead
- ADMA elevation does not exacerbate development of diabetic nephropathy in mice with streptozotocin-induced diabetes mellitus590 daysAtherosclerosis SupplementsRead
- Cardiovascular risk factors in patients with premature cardiovascular events attending the University of Dresden Lipid Clinic590 daysAtherosclerosis SupplementsRead
- Serum uric acid and left ventricular geometry pattern in obese children590 daysAtherosclerosis SupplementsRead
- Efficiency and problems of statin therapy in patients with heterozygous familial hypercholesterolemia590 daysAtherosclerosis SupplementsRead
- Statin-induced muscular side effects at rest and exercise – An anatomical mapping590 daysAtherosclerosis SupplementsRead
- Effectiveness of different immunoadsorption columns for anti-A/B antibody depletion590 daysAtherosclerosis SupplementsRead
- Apheresis as emerging treatment option in severe early onset preeclampsia590 daysAtherosclerosis SupplementsRead
- Immunoadsorption in nephrotic syndrome: Where are we now and where are we going from here?590 daysAtherosclerosis SupplementsRead
- Optical coherence tomography of retinal and choroidal layers in patients with familial hypercholesterolaemia treated with lipoprotein apheresis590 daysAtherosclerosis SupplementsRead
- One year follow-up of patients with reduced left ventricular ejection fraction (LVEF) on lipoprotein apheresis590 daysAtherosclerosis SupplementsRead
- Experience with proprotein convertase subtilisin/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresis590 daysAtherosclerosis SupplementsRead
- Short- and long-term effects of lipoprotein apheresis on plasma hormones in patients with therapy-resistant dyslipidemia590 daysAtherosclerosis SupplementsRead
- Lipoprotein apheresis in Germany – Still more commonly indicated than implemented. How can patients in need access therapy?590 daysAtherosclerosis SupplementsRead
- Lipoprotein(a) – Marker for cardiovascular risk and target for lipoprotein apheresis590 daysAtherosclerosis SupplementsRead
- Influence of lipoprotein apheresis on circulating plasma levels of miRNAs in patients with high Lp(a)590 daysAtherosclerosis SupplementsRead
- Lipoprotein apheresis in Austria – Reduction of cardiovascular events by regular lipoprotein apheresis treatment590 daysAtherosclerosis SupplementsRead
- Actual situation of lipoprotein apheresis in patients with elevated lipoprotein(a) levels590 daysAtherosclerosis SupplementsRead
- Corrigendum to “Monascus purpureus for statin and ezetimibe intolerant heterozygous familial hypercholesterolaemia patients: A clinical study” [Atherosclerosis (Supplements) 30C (2017) 86–91]590 daysAtherosclerosis SupplementsRead
- Medicine - All Feeds
- Allergology and Immunology
- Anatomy and Physiology
- Anesthesiology and Intensive Care
- Biochemistry
- Bioengineering
- Biophysics
- Biotechnology
- Cardiology
- Cardiothoracic Surgery
- Clinical Chemistry
- Clinical Medicine
- Complementary Medicine
- Cytology and Histology
- Dentistry
- Dermatology
- Endocrinology
- Forensic Medicine
- Gastroenterology
- General Practice
- Genetics
- Geriatrics
- Health services and Administration
- Hematology
- Infectious Diseases
- Internal Medicine
- Logopedics
- Medical Education and Humanities
- Medical Microbiology
- Medicine - Other
- Nephrology
- Neurology
- Neurosurgery
- Nursing
- Nutritional Sciences
- Obstetrics and Gynecology
- Occupational Health
- Oncology
- Ophthalmology
- Oral and Maxillofacial Surgery
- Orthopedics and Traumatology
- Otorhinolaryngology and Phoniatrics
- Pathology
- Pediatrics
- Pharmacology and Pharmacotherapy
- Physical and Rehabilitation Medicine
- Plastic Surgery
- Psychiatry
- Psychology
- Public Health
- Radiology
- Respiratory Medicine
- Rheumatology
- Sports Medicine
- Surgery
- Urology